Prior Experience: Hoffman has a long history in th
Post# of 156547
(Total Views: 2789)
Posted On: 08/29/2025 7:03:12 AM
Prior Experience: Hoffman has a long history in the biotech and biopharmaceutical sectors, serving in executive and board roles at several companies, including:
President, CEO, and Chairman of the board of Kintara Therapeutics, Inc.
Senior Vice President, Finance, and CFO of Arena Pharmaceuticals, Inc. (prior to its acquisition by Pfizer).
CFO of AnaptysBio, Inc., and Heron Therapeutics, Inc.
Board Membership: He has served on the boards of directors for multiple companies, including Esperion Therapeutics, Inc., TuHURA Biosciences, Inc., FibroBiologics, Inc., Antibe Therapeutics Inc., and others.
Financial Advisement: H.C. Wainwright & Co. served as the exclusive financial advisor to TuHURA Biosciences in its merger with Kintara Therapeutics. This role indicates a professional, transactional relationship where H.C. Wainwright provided financial guidance and expertise for the merger. The merger was announced in April 2024 and completed in October 2024, at which point the combined company was renamed TuHURA Biosciences.
Conference Participation: Kintara Therapeutics, while it existed as a separate entity, presented at various H.C. Wainwright conferences. For example, Kintara's President and CEO, Saiid Zarrabian, presented at the H.C. Wainwright Bioconnect 2021 Virtual Conference. This is a common practice for smaller and mid-sized biotechnology companies to gain exposure to investors.
Robert E. Hoffman's Role: Robert E. Hoffman was the President and Chief Executive Officer of Kintara Therapeutics from November 2021 until the merger with TuHURA in October 2024. He also served as the chairman and a director of Kintara. His involvement with Kintara during this time would have included interacting with financial institutions like H.C. Wainwright in their various capacities.
Another Robert Hoffman's deals
Pfizer acquired Arena Pharmaceuticals for a total equity value of approximately $6.7 billion. The acquisition was completed in March 2022, with Pfizer paying $100 per share in an all-cash transaction. This represented more than double the company's closing stock price on the Friday before the deal was announced in December 2021.
https://www.biospace.com/press-releases/cytod...conference
President, CEO, and Chairman of the board of Kintara Therapeutics, Inc.
Senior Vice President, Finance, and CFO of Arena Pharmaceuticals, Inc. (prior to its acquisition by Pfizer).
CFO of AnaptysBio, Inc., and Heron Therapeutics, Inc.
Board Membership: He has served on the boards of directors for multiple companies, including Esperion Therapeutics, Inc., TuHURA Biosciences, Inc., FibroBiologics, Inc., Antibe Therapeutics Inc., and others.
Financial Advisement: H.C. Wainwright & Co. served as the exclusive financial advisor to TuHURA Biosciences in its merger with Kintara Therapeutics. This role indicates a professional, transactional relationship where H.C. Wainwright provided financial guidance and expertise for the merger. The merger was announced in April 2024 and completed in October 2024, at which point the combined company was renamed TuHURA Biosciences.
Conference Participation: Kintara Therapeutics, while it existed as a separate entity, presented at various H.C. Wainwright conferences. For example, Kintara's President and CEO, Saiid Zarrabian, presented at the H.C. Wainwright Bioconnect 2021 Virtual Conference. This is a common practice for smaller and mid-sized biotechnology companies to gain exposure to investors.
Robert E. Hoffman's Role: Robert E. Hoffman was the President and Chief Executive Officer of Kintara Therapeutics from November 2021 until the merger with TuHURA in October 2024. He also served as the chairman and a director of Kintara. His involvement with Kintara during this time would have included interacting with financial institutions like H.C. Wainwright in their various capacities.
Another Robert Hoffman's deals
Pfizer acquired Arena Pharmaceuticals for a total equity value of approximately $6.7 billion. The acquisition was completed in March 2022, with Pfizer paying $100 per share in an all-cash transaction. This represented more than double the company's closing stock price on the Friday before the deal was announced in December 2021.
https://www.biospace.com/press-releases/cytod...conference
(7)
(0)